The CRO/CMO community in Massachusetts consists of a range of vibrant organizations partnering with pharmaceutical and biotech companies developing important new medicines. This segment of our life sciences community delivers many of the key activities needed for new drugs to move through the complex phases of development.
MassBio has kicked off a new series of educational Forums highlighting the role of the CRO/CMO segment. The first segment, Current Trends and Best Practices in Outsourcing Part 1: Early Stage Drug Development, was held on September 15th and emphasized the interplay between developers and CROs during the early phase of drug development.
Session highlights included:
The differing outsourcing needs of larger vs smaller biotech companies.
The strong desire of drug developers to work with CROs with a high level of flexibility and responsiveness.
Working directly with the scientific team at a CRO.
Part two will be held on October 20th and is entitled Current Trends and Best Practices in Outsourcing Part II: Early Stage Clinical Manufacturing. Leaders in the biotech and pharmaceutical industries will gather to share their experiences in early stage clinical manufacturing.
Topics to be covered include:
cGMP manufacturing
What to look for in a CMO
Regulatory considerations
This upcoming forum, along with the CRO/CMO Symposium to be held on November 13th, provides a unique opportunity for those in the pharma R&D community to gather and explore best practices in developing successful collaborations. There is also an opportunity for the respective CROs & CMOs participating in these events to meet and learn more about one another. The many synergies between our organizations provide an opportunity to share ideas and enhance the high quality services currently in demand in our industry.